Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Hematology & Oncology
Published in: Journal of Hematology & Oncology 1/2013

Open Access 01-12-2013 | Review

Biomarkers for determining the prognosis in chronic myelogenous leukemia

Authors: Kendra Sweet, Ling Zhang, Javier Pinilla-Ibarz

Published in: Journal of Hematology & Oncology | Issue 1/2013

Login to get access

Abstract

The introduction of BCR-ABL1 tyrosine kinase inhibitors (TKIs) for treatment of chronic myelogenous leukemia in chronic phase (CML-CP) has revolutionized therapy, altering the outcome from one of shortened life expectancy to long-term survival. With over 10 years of long-term treatment with imatinib and several years of experience with the next generation of TKIs, including nilotinib, dasatinib, bosutinib, and ponatinib, it is becoming clear that many clinical parameters have great impact on the prognosis of patients with CML. Emerging novel gene expression profiling and molecular techniques also provide new insights into CML pathogenesis and have identified potential prognostic markers and therapeutic targets. This review presents the supporting data and discusses how certain clinical characteristics at diagnosis, the depth of early response, the presence of certain kinase domain mutations, and additional molecular changes serve as prognostic factors that may guide individualized treatment decisions for patients with CML-CP.
Appendix
Available only for authorised users
Literature
1.
Deininger MW, Goldman JM, Melo JV: The molecular biology of chronic myeloid leukemia. Blood. 2000, 96 (10): 3343-3356.PubMed
2.
Baccarani M, Castagnetti F, Gugliotta G, Palandri F, Soverini S: Response definitions and European Leukemianet Management recommendations. Best Pract Res Clin Haematol. 2009, 22 (3): 331-341. 10.1016/j.beha.2009.10.001.CrossRefPubMed
3.
Novartis Pharmaceuticals Corporation: Gleevec (imatinib mesylate) [prescribing information]. 2009, East Hanover, NJ: Novartis Pharmaceuticals Corporation
4.
Gambacorti-Passerini C, Valletta S, Stasia A, Leeksma A, Sharma N, Rizzo C, Pogliani EM, Pirola A, Piazza R: CML patients present additional mutations in cancer related genes when tested at diagnosis [abstract]. Blood (ASH Annual Meeting Abstracts). 2011, 118 (21): 2739-
5.
6.
Bristol-Myers Squibb Company: Sprycel (dasatinib) [prescribing information]. 2013, Princeton, NJ: Bristol-Myers Squibb Company
7.
Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, Moiraghi B, Shen Z, Mayer J, Pasquini R, Nakamae H, Huguet F, Boque C, Chuah C, Bleickardt E, Bradley-Garelik MB, Zhu C, Szatrowski T, Shapiro D, Baccarani M: Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010, 362 (24): 2260-2270. 10.1056/NEJMoa1002315.CrossRefPubMed
8.
Novartis Pharmaceuticals Corporation: Tasigna (nilotinib) [prescribing information]. 2012, East Hanover, NJ: Novartis Pharmaceuticals Corporation, May
9.
Saglio G, Kantarjian HM, Shah N, Jabbour EJ, Quintas-Cardama A, Steegmann JL, Boque C, Chuah C, Pavlovsky C, Mayer J, Ukropec J, Wildgust M, Hochhaus A: Early response (molecular and cytogenetic) and long-term outcomes in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): Exploratory analysis of DASISION 3-year data [abstract]. Blood (ASH Annual Meeting Abstracts). 2012, 120 (21): 1675-
10.
Kantarjian HM, Hochhaus A, Saglio G, De Souza C, Flinn IW, Stenke L, Goh YT, Rosti G, Nakamae H, Gallagher NJ, Hoenekopp A, Blakesley RE, Larson RA, Hughes TP: Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol. 2011, 12 (9): 841-851. 10.1016/S1470-2045(11)70201-7.CrossRefPubMed
11.
Kantarjian H, Flinn IW, Goldberg S, Bunworasate U, Zanichelli MA, Nakamae H, Hughes TP, Hochhaus A, Saglio G, Woodman RC, Blakesley RE, Kemp CN, Kalaycio ME, Larson RA: Nilotinib versus imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd 3-year (yr) follow-up (f/u) [abstract]. J Clin Oncol (ASCO Annual Meeting Abstracts). 2012, 30 (suppl): 6509-
12.
Hochhaus A, Shah NP, Cortes JE, Baccarani M, Bradley-Garelik MB, Dejardin D, Kantarjian H: Dasatinib versus imatinib (IM) in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): DASISION 3-year follow-up [abstract]. J Clin Oncol (ASCO Annual Meeting Abstracts). 2012, 30 (suppl): 6504-
13.
Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE, Tso CY, Braun TJ, Clarkson BD, Cervantes F: Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood. 1984, 63 (4): 789-799.PubMed
14.
Hasford J, Pfirrmann M, Hehlmann R, Allan NC, Baccarani M, Kluin-Nelemans JC, Alimena G, Steegmann JL, Ansari H: A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst. 1998, 90 (11): 850-858. 10.1093/jnci/90.11.850.CrossRefPubMed
15.
Hasford J, Baccarani M, Hoffmann V, Guilhot J, Saussele S, Rosti G, Guilhot F, Porkka K, Ossenkoppele G, Lindoerfer D, Simonsson B, Pfirrmann M, Hehlmann R: Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood. 2011, 118 (3): 686-692. 10.1182/blood-2010-12-319038.CrossRefPubMed
16.
Saussele S, Lauseker M, Hoffmann V, Proetel U, Hanfstein B, Baerlocher GM, Heim D, Ehninger G, Hossfeld DK, Kolb H-J, Krause SW, Nerl C, Pralle H, Schubert JEA, Einsele H, Hanel M, Ho AD, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Spiekermann K, Schnittger S, Pfirrmann M, Hochhaus A, Hasford J, Hehlmann R: Prediction of molecular response of chronic phase CML patients by the EUTOS score: results of the randomized CML-Study IV [abstract]. Blood (ASH Annual Meeting Abstracts). 2011, 118 (21): 3762-
17.
Marin D, Ibrahim AR, Goldman JM: European Treatment and Outcome Study (EUTOS) score for chronic myeloid leukemia still requires more confirmation. J Clin Oncol. 2011, 29 (29): 3944-3945. 10.1200/JCO.2011.37.6962.CrossRefPubMed
18.
Jabbour E, Cortes J, Nazha A, O'Brien S, Quintas-Cardama A, Pierce S, Garcia-Manero G, Kantarjian H: EUTOS score is not predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single institution experience. Blood. 2012, 119 (19): 4524-4526. 10.1182/blood-2011-10-388967.PubMedCentralCrossRefPubMed
19.
Kantarjian HM, Shah NP, Cortes JE, Baccarani M, Agarwal MB, Undurraga MS, Wang J, Ipina JJ, Kim DW, Ogura M, Pavlovsky C, Junghanss C, Milone JH, Nicolini FE, Robak T, Van Droogenbroeck J, Vellenga E, Bradley-Garelik MB, Zhu C, Hochhaus A: Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood. 2012, 119 (5): 1123-1129. 10.1182/blood-2011-08-376087.CrossRefPubMed
20.
Cortes JE, Kim DW, Kantarjian HM, Brummendorf TH, Dyagil I, Griskevicus L, Malhotra H, Powell C, Gogat K, Countouriotis AM, Gambacorti-Passerini C: Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA Trial. J Clin Oncol. 2012, 30 (28): 3486-3492. 10.1200/JCO.2011.38.7522.CrossRefPubMed
21.
Trask P, Mitra D, Iyer S, Candrilli S, Kaye J: Patterns and prognostic indicators of response to CML treatment in a multi-country medical record review study. Int J Hematol. 2012, 95 (5): 535-544. 10.1007/s12185-012-1043-8.CrossRefPubMed
22.
Saglio G, Kim DW, Issaragrisil S, Le Coutre P, Etienne G, Lobo C, Pasquini R, Clark RE, Hochhaus A, Hughes TP, Gallagher N, Hoenekopp A, Dong M, Haque A, Larson RA, Kantarjian HM: Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010, 362 (24): 2251-2259. 10.1056/NEJMoa0912614.CrossRefPubMed
23.
Verma D, Kantarjian H, Shan J, O'Brien S, Estrov Z, Garcia-Manero G, Koller C, Borthakur G, Cortes J: Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy. Cancer. 2010, 116 (11): 2673-2681.PubMedCentralPubMed
24.
Fabarius A, Leitner A, Hochhaus A, Muller MC, Haferlach C, Gohring G, Schlegelberger B, Jotterand M, Reiter A, Jung-Munkwitz S, Proetel U, Schwaab J, Hofmann W-K, Schubert JEA, Einsele H, Ho AD, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Hiddemann W, Baerlocher GM, Lauseker M, Pfirrmann M, Saussele S, Hehlmann R, Hasford J: Impact of additional cytogenetic alterations at diagnosis on prognosis of CML: long-term observation from 1151 patients of the randomized CML Study IV [abstract]. Blood (ASH Annual Meeting Abstracts). 2011, 118 (21): 782-
25.
Cortes JE, Talpaz M, Giles F, O'Brien S, Rios MB, Shan J, Garcia-Manero G, Faderl S, Thomas DA, Wierda W, Ferrajoli A, Jeha S, Kantarjian HM: Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. Blood. 2003, 101 (10): 3794-3800. 10.1182/blood-2002-09-2790.CrossRefPubMed
26.
Kim TD, Turkmen S, Schwarz M, Koca G, Nogai H, Bommer C, Dorken B, Daniel P, Le Coutre P: Impact of additional chromosomal aberrations and BCR-ABL kinase domain mutations on the response to nilotinib in Philadelphia chromosome-positive chronic myeloid leukemia. Haematologica. 2010, 95 (4): 582-588. 10.3324/haematol.2009.014712.PubMedCentralCrossRefPubMed
27.
Lahaye T, Riehm B, Berger U, Paschka P, Muller MC, Kreil S, Merx K, Schwindel U, Schoch C, Hehlmann R, Hochhaus A: Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up. Cancer. 2005, 103 (8): 1659-1669. 10.1002/cncr.20922.CrossRefPubMed
28.
Albano F, Anelli L, Zagaria A, Coccaro N, Casieri P, Rossi AR, Vicari L, Liso V, Rocchi M, Specchia G: Non random distribution of genomic features in breakpoint regions involved in chronic myeloid leukemia cases with variant t(9;22) or additional chromosomal rearrangements. Mol Cancer. 2010, 9: 120-10.1186/1476-4598-9-120.PubMedCentralCrossRefPubMed
29.
Brahmbhatt MM, Trivedi PJ, Dalal EN, Patel DM, Purani SS, Shukla SN, Shah PM, Patel PS: ABL/BCR gene variant with two-step mechanism: Unusual localization and rare/novel chromosomal rearrangements in CML patients. J Assoc Genet Technol. 2011, 37 (2): 69-75.PubMed
30.
El-Zimaity MM, Kantarjian H, Talpaz M, O'Brien S, Giles F, Garcia-Manero G, Verstovsek S, Thomas D, Ferrajoli A, Hayes K, Nebiyou Bekele B, Zhou X, Rios MB, Glassman AB, Cortes JE: Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosome. Br J Haematol. 2004, 125 (2): 187-195. 10.1111/j.1365-2141.2004.04899.x.CrossRefPubMed
31.
Valencia A, Cervera J, Such E, Barragan E, Bolufer P, Fuster O, Collado R, Martinez J, Sanz MA: Complex variant t(9;22) chromosome translocations in five cases of chronic myeloid leukemia. Adv Hematol. 2009, 2009: 187125-PubMedCentralCrossRefPubMed
32.
Stagno F, Vigneri P, Del Fabro V, Stella S, Cupri A, Massimino M, Consoli C, Tambe L, Consoli ML, Antolino A, Di Raimondo F: Influence of complex variant chromosomal translocations in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors. Acta Oncol. 2010, 49 (4): 506-508. 10.3109/02841861003660031.CrossRefPubMed
33.
Tantiworawit A, Abou Mourad Y, Barnett MJ, Broady R, Hogge DE, Nantel SH, Narayanan S, Nevill TJ, Power MM, Shepherd JD, Song KW, Sutherland HJ, Toze CL, Forrest DL: Clonal evolution but not variant chromosomal translocations is an adverse prognostic marker for cytogenetic response and survival in CML patients treated with imatinib [abstract]. Blood (ASH Annual Meeting Abstracts). 2011, 118 (21): 1694-
34.
Gorusu M, Benn P, Li Z, Fang M: On the genesis and prognosis of variant translocations in chronic myeloid leukemia. Cancer Genet Cytogenet. 2007, 173 (2): 97-106. 10.1016/j.cancergencyto.2006.10.006.CrossRefPubMed
35.
Shah BD, Zhang L, Bulkeley W, Moscinski L, Papenhausen P, Pinilla-Ibarz J: Outcome of complex variant Philadelphia positive chromosome translocations in the era of tyrosine kinase inhibitors [abstract]. Blood (ASH Annual Meeting Abstracts). 2011, 118 (21): 3788-
36.
Hehlmann R, Hanfstein B, Muller MC, Erben P, Lauseker M, Fabarius A, Schnittger S, Haferlach C, Goehring G, Krause SW, Dengler J, Falge C, Neubauer A, Stegelmann F, Pfeundschuh M, Spiekermann K, Baerlocher GM, Hasford J, Saussele S, Hochhaus A: Group AftSatGCS: The prognostic significance of early molecular and cytogenetic response for long-term progression-free and overall survival in imatinib-treated chronic myeloid leukemia (CML) [abstract]. J Clin Oncol. 2012, 30 (15 suppl): 6510-
37.
Lucas CM, Harris RJ, Giannoudis A, Davies A, Knight K, Watmough SJ, Wang L, Clark RE: Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript. Haematologica. 2009, 94 (10): 1362-1367. 10.3324/haematol.2009.009134.PubMedCentralCrossRefPubMed
38.
Hanfstein B, Erben P, Saussele S, Lauseker M, Proetel U, Haag S, Schnittger S, Haferlach C, Kolb H-J, Krause SW, Nerl C, Heim D, Baerlocher GM, Schubert JEA, Einsele H, Hanel M, Dengler J, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Pfirrmann M, Hasford J, Hofmann W-K, Hehlmann R, Hochhaus A, Muller MC: Distinct characteristics of e13a2 versus e14a2 BCR-ABL chronic myeloid leukemia under upfront treatment with imatinib - an analysis of the German CML Study IV [abstract]. Blood (ASH Annual Meeting Abstracts). 2011, 118 (21): 3773-
39.
White DL, Saunders VA, Dang P, Engler J, Zannettino AC, Cambareri AC, Quinn SR, Manley PW, Hughes TP: OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood. 2006, 108 (2): 697-704. 10.1182/blood-2005-11-4687.CrossRefPubMed
40.
White DL, Dang P, Engler J, Frede A, Zrim S, Osborn M, Saunders VA, Manley PW, Hughes TP: Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib. J Clin Oncol. 2010, 28 (16): 2761-2767. 10.1200/JCO.2009.26.5819.CrossRefPubMed
41.
Hiwase DK, Saunders V, Hewett D, Frede A, Zrim S, Dang P, Eadie L, To LB, Melo J, Kumar S, Hughes TP, White DL: Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications. Clin Cancer Res. 2008, 14 (12): 3881-3888. 10.1158/1078-0432.CCR-07-5095.CrossRefPubMed
42.
ARIAD Pharmaceuticals, Inc: Iclusig (ponatinib) [prescribing information]. 2012, Cambridge, MA: ARIAD Pharmaceuticals, Inc
43.
Pfizer Labs: Bosulif (bosutinib) [prescribing information]. 2012, New York, NY: Pfizer Labs
44.
Picard S, Titier K, Etienne G, Teilhet E, Ducint D, Bernard MA, Lassalle R, Marit G, Reiffers J, Begaud B, Moore N, Molimard M, Mahon FX: Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood. 2007, 109 (8): 3496-3499. 10.1182/blood-2006-07-036012.CrossRefPubMed
45.
Larson RA, Druker BJ, Guilhot F, O'Brien SG, Riviere GJ, Krahnke T, Gathmann I, Wang Y: Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood. 2008, 111 (8): 4022-4028. 10.1182/blood-2007-10-116475.CrossRefPubMed
46.
Faber E, Friedecky D, Micova K, Rozmanova S, Divoka M, Jarosova M, Indrak K, Adam T: Imatinib trough plasma levels do not correlate with the response to therapy in patients with chronic myeloid leukemia in routine clinical setting. Ann Hematol. 2012, 91 (6): 923-929. 10.1007/s00277-011-1394-x.CrossRefPubMed
47.
Koren-Michowitz M, Volchek Y, Naparstek E, Gavish I, Levi I, Rowe JM, Shimoni A, Nagler A: Imatinib plasma trough levels in chronic myeloid leukaemia: results of a multicentre study CSTI571AIL11TGLIVEC. Hematol Oncol. 2012, 30 (4): 200-205. 10.1002/hon.2005.CrossRefPubMed
48.
Sohn SK, Oh SJ, Kim BS, Ryoo HM, Chung JS, Joo YD, Bang SM, Jung CW, Kim DH, Yoon SS, Kim H, Lee HG, Won JH, Min YH, Cheong JW, Park JS, Eom KS, Hyun MS, Kim MK, Park MR, Park J, Kim CS, Kim HJ, Kim YK, Park EK, Zang DY, Jo DY, Moon JH, Park SY: Trough plasma imatinib levels are correlated with optimal cytogenetic responses at 6 months after treatment with standard dose of imatinib in newly diagnosed chronic myeloid leukemia. Leuk Lymphoma. 2011, 52 (6): 1024-1029. 10.3109/10428194.2011.563885.CrossRefPubMed
49.
Hughes TP, Hochhaus A, Branford S, Muller MC, Kaeda JS, Foroni L, Druker BJ, Guilhot F, Larson RA, O'Brien SG, Rudoltz MS, Mone M, Wehrle E, Modur V, Goldman JM, Radich JP: Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood. 2010, 116 (19): 3758-3765. 10.1182/blood-2010-03-273979.PubMedCentralCrossRefPubMed
50.
Hanfstein B, Muller MC, Hehlmann R, Erben P, Lauseker M, Fabarius A, Schnittger S, Haferlach C, Gohring G, Proetel U, Kolb HJ, Krause SW, Hofmann WK, Schubert J, Einsele H, Dengler J, Hanel M, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Branford S, Hughes TP, Spiekermann K, Baerlocher GM, Pfirrmann M, Hasford J: Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia. 2012, 26 (9): 2096-2102. 10.1038/leu.2012.85.CrossRefPubMed
51.
Marin D, Ibrahim AR, Lucas C, Gerrard G, Wang L, Szydlo RM, Clark RE, Apperley JF, Milojkovic D, Bua M, Pavlu J, Paliompeis C, Reid A, Rezvani K, Goldman JM, Foroni L: Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol. 2012, 30 (3): 232-238. 10.1200/JCO.2011.38.6565.CrossRefPubMed
52.
Hochhaus A, Hughes TP, Saglio G, Guilhot F, Al-Ali HK, Rosti G, Nakaseko C, De Souza CA, Kemp C, Fan X, Hoenekopp A, Larson RA, Kantarjian HM: Outcome of patients with chronic myeloid leukemia in chronic phase (CML-CP) based on early molecular response and factors associated with early response: 4-year follow-up data from ENESTnd (Evaluating Nilotinib Efficacy and Safety in Clinical Trials Newly Diagnosed Patients) [abstract]. Blood (ASH Annual Meeting Abstracts). 2012, 120 (21): 167-
53.
Brummendorf TH, Kantarjian HM, Gambacorti-Passerini C, Guilhot F, Akard L, Doshi V, Lipton JH, Pavlov D, Gogat K, Duvillie L, Shapiro M, Cortes JE: Assessment of early molecular response as a predictor of long-term clinical outcomes in the phase 3 BELA Study [abstract]. Blood (ASH Annual Meeting Abstracts). 2012, 120 (21): 69-
54.
Naqvi K, Kantarjian HM, Luthra R, Jabbour E, O'Brien S, Burton EM, Verstovsek S, Ravandi F, Wierda WG, Borthakur G, Quintas-Cardama A, Cortes JE: Kinetics of molecular response with different tyrosine kinase inhibitors (TKI) used as frontline therapy in chronic myeloid leukemia-chronic phase (CML CP) [abstract]. Blood (ASH Annual Meeting Abstracts). 2011, 118 (21): 3784-
55.
Nicolini FE, Hayette S, Labussiere H, Etienne M, Fort M-P, Gadolet E, Tigaud I, Chabane K, Lippert E, Sobh M, Dulucq S, Morisset S, Michallet M, Mahon F-X, Etienne G: The month three major molecular response in chronic phase chronic myeloid leukemia on imatinib 400, nilotinib and dasatinib is a major prognostic factor for failure-free and progression-free survival [abstract]. Blood (ASH Annual Meeting Abstracts). 2011, 118 (21): 1684-
56.
Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, Pane F, Muller MC, Ernst T, Rosti G, Porkka K, Baccarani M, Cross NC, Martinelli G: BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood. 2011, 118 (5): 1208-1215. 10.1182/blood-2010-12-326405.CrossRefPubMed
57.
Soverini S, Martinelli G, Rosti G, Bassi S, Amabile M, Poerio A, Giannini B, Trabacchi E, Castagnetti F, Testoni N, Luatti S, De Vivo A, Cilloni D, Izzo B, Fava M, Abruzzese E, Alberti D, Pane F, Saglio G, Baccarani M: ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia. J Clin Oncol. 2005, 23 (18): 4100-4109. 10.1200/JCO.2005.05.531.CrossRefPubMed
58.
Willis SG, Lange T, Demehri S, Otto S, Crossman L, Niederwieser D, Stoffregen EP, McWeeney S, Kovacs I, Park B, Druker BJ, Deininger MW: High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy. Blood. 2005, 106 (6): 2128-2137. 10.1182/blood-2005-03-1036.CrossRefPubMed
59.
Soverini S, Gnani A, De Benedittis C, Castagnetti F, Gugliotta G, Iacobucci I, Palandri F, Rosti G, Testoni N, Luatti S, Marzocchi G, Baccarani M, Martinelli G: Low-level Bcr-Abl mutations are very rare in chronic myeloid leukemia patients who are in major molecular response on first-line nilotinib. Leuk Res. 2011, 35 (11): 1527-1529. 10.1016/j.leukres.2011.05.029.CrossRefPubMed
60.
Parker WT, Lawrence RM, Ho M, Irwin DL, Scott HS, Hughes TP, Branford S: Sensitive detection of BCR-ABL1 mutations in patients with chronic myeloid leukemia after imatinib resistance is predictive of outcome during subsequent therapy. J Clin Oncol. 2011, 29 (32): 4250-4259. 10.1200/JCO.2011.35.0934.CrossRefPubMed
61.
Yong AS, Melo JV: The impact of gene profiling in chronic myeloid leukaemia. Best Pract Res Clin Haematol. 2009, 22 (2): 181-190. 10.1016/j.beha.2009.04.002.CrossRefPubMed
62.
McWeeney SK, Pemberton LC, Loriaux MM, Vartanian K, Willis SG, Yochum G, Wilmot B, Turpaz Y, Pillai R, Druker BJ, Snead JL, MacPartlin M, O'Brien SG, Melo JV, Lange T, Harrington CA, Deininger MW: A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib. Blood. 2010, 115 (2): 315-325. 10.1182/blood-2009-03-210732.PubMedCentralCrossRefPubMed
63.
Radich JP, Dai H, Mao M, Oehler V, Schelter J, Druker B, Sawyers C, Shah N, Stock W, Willman CL, Friend S, Linsley PS: Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci USA. 2006, 103 (8): 2794-2799. 10.1073/pnas.0510423103.PubMedCentralCrossRefPubMed
64.
Oehler VG, Yeung KY, Choi YE, Bumgarner RE, Raftery AE, Radich JP: The derivation of diagnostic markers of chronic myeloid leukemia progression from microarray data. Blood. 2009, 114 (15): 3292-3298. 10.1182/blood-2009-03-212969.PubMedCentralCrossRefPubMed
65.
Yeung KY, Gooley TA, Zhang A, Raftery AE, Radich JP, Oehler VG: Predicting relapse prior to transplantation in chronic myeloid leukemia by integrating expert knowledge and expression data. Bioinformatics. 2012, 28 (6): 823-830. 10.1093/bioinformatics/bts059.PubMedCentralCrossRefPubMed
66.
Quintas-Cardama A, Qiu YH, Post S, Zhang Y, Creighton C, Cortes JE, Kornblau SM: Proteomic profiling of 112 proteins in chronic myeloid leukemia patient samples using reverse phase proteins arrays (RPPA) reveals distinct protein expression signatures associated with advanced phase disease and the CD34+ compartment [abstract]. Blood (ASH Annual Meeting Abstracts). 2011, 118 (21): 2503-
67.
Gonzalez MS, De Brasi CD, Bianchini M, Ferri C, Bengio R, Larripa IB: Expression of CAMKIIγ, HSP70 and HSP90 genes are differentially associated with the mutational status of tirosine kinase domain in chronic myeloid leukemia resistant patients [abstract]. Blood (ASH Annual Meeting Abstracts). 2011, 118 (21): 4877-
Metadata
Title
Biomarkers for determining the prognosis in chronic myelogenous leukemia
Authors
Kendra Sweet
Ling Zhang
Javier Pinilla-Ibarz
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Journal of Hematology & Oncology / Issue 1/2013
Electronic ISSN: 1756-8722
DOI
https://doi.org/10.1186/1756-8722-6-54

Other articles of this Issue 1/2013

Journal of Hematology & Oncology 1/2013 Go to the issue

Research

Inhibition of Hedgehog signaling sensitizes NSCLC cells to standard therapies through modulation of EMT-regulating miRNAs

Commentary

Lynch syndrome related endometrial cancer: clinical significance beyond the endometrium

Short report

Induction of long intergenic non-coding RNA HOTAIR in lung cancer cells by type I collagen

Research

Detection of TP53 dysfunction in chronic lymphocytic leukemia by an in vitro functional assay based on TP53 activation by the non-genotoxic drug Nutlin-3: a proposal for clinical application

Review

Targeting p53 by small molecules in hematological malignancies

Research

Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits